In the last few years, Saudi Arabia has been expanding its efforts to advance the vaccine localization strategy through various initiatives. Recently, Public Investment Fund’s (PIF) -owned biopharmaceutical firm Lifera joined hands with French pharmaceutical company Sanofi and Saudi manufacturer Arabio to explore possibilities of vaccine manufacturing. This collaboration is also expected to transfer world-class technology and expertise to Saudi Arabia while providing local citizens with high-quality vaccines. 

“As a newly established biopharmaceutical company, we are committed to working with global and local partners to achieve our mission– and this MoU is a testament to that commitment,” says Ibrahim Aljufalli, Lifera’s chairman. 

The partnership with Arabio, partly owned by Tamer Group, will help strengthen the local and regional distribution of vaccines. 

Fokion Sinis, vaccines general manager for Sanofi in the Greater Gulf, says, “This MoU further builds on this commitment, enabling us to share our global expertise and contribute to advancing the public health agenda and industrial sector development of the country, ultimately benefiting patients and communities in Saudi Arabia.”